Tang et al listed risk factors associated with hyperkalemia in a patient treated with a drug that inhibits the renin-angiotensin-aldosterone system such as an aldosterone receptor antagonist. A patient with one or more of these risk factors should be monitored for hyperkalemia during therapy with one of these agents.
